Marc G. Achen

Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo.

The role of tumor lymphangiogenesis in metastatic spread.

The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.

Lymphangiogenesis and cancer metastasis.

Molecular control of lymphangiogenesis.

Regenerating lizard tails: a new model for investigating lymphangiogenesis.

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.

Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens.

Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.

Vascular endothelial growth factor-D expression in human atherosclerotic lesions.

Angiogenic responses of vascular endothelial growth factors in periadventitial tissue.

Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart.

Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.

Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis.

Lymphangiogenic growth factors as markers of tumor metastasis.

Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.

Focus on lymphangiogenesis in tumor metastasis.

Vascular endothelial growth factor D is dispensable for development of the lymphatic system.

Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.

Lymphatic endothelium: an important interactive surface for malignant cells.

A Simple and Rapid Method for Genetic Transformation of Lactic Streptococci by Electroporation.

Mechanisms of lymphangiogenesis: targets for blocking the metastatic spread of cancer.

Tumor lymphangiogenesis and metastatic spread-new players begin to emerge.

Lymphatic vessels in cancer metastasis: bridging the gaps.

Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.

Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2.

Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis.

Molecular pathways for lymphangiogenesis and their role in human disease.

A system for quantifying the patterning of the lymphatic vasculature.

Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos.

Molecular control of lymphatic metastasis.

Targeting tumor stroma.

Sox18 induces development of the lymphatic vasculature in mice.

From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy.

Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.

Targeting lymphatic vessel functions through tyrosine kinases.

The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding.

Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer.

A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth.

Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies.

VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.

Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis.

Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.

Remodeling of the lymphatic vasculature during mouse mammary gland morphogenesis is mediated via epithelial-derived lymphangiogenic stimuli.

The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.

Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis.

The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.

The VEGF signaling pathway in cancer: the road ahead.

Vascular endothelial growth factor-d modulates caliber and function of initial lymphatics in the dermis.

Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Arap3 is dysregulated in a mouse model of hypotrichosis-lymphedema-telangiectasia and regulates lymphatic vascular development.

Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.

VEGFD regulates blood vascular development by modulating SOX18 activity.

The proteolytic activation of angiogenic and lymphangiogenic growth factors in cancer--its potential relevance for therapeutics and diagnostics.

Ccbe1 regulates Vegfc-mediated induction of Vegfr3 signaling during embryonic lymphangiogenesis.

Lymphangiogenesis and lymphatic vessel remodelling in cancer.

Exploring the role of endothelium in the tumour response to anti-angiogenic therapy.

Vegf-d promotes pulmonary oedema in hyperoxic acute lung injury.